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Purpose—Next-generation sequencing (NGS) based methods are being adopted broadly for 
genetic diagnostic testing, but the performance characteristics of these techniques have not been 
fully defined with regard to test accuracy and reproducibility.
Methods—We developed a targeted enrichment and NGS approach for genetic diagnostic testing 
of patients with inherited eye disorders, including inherited retinal degenerations, optic atrophy 
and glaucoma. In preparation for providing this Genetic Eye Disease (GEDi) test on a CLIA-
certified basis, we performed experiments to measure the sensitivity, specificity, reproducibility as 
well as the clinical sensitivity of the test.
Results—The GEDi test is highly reproducible and accurate, with sensitivity and specificity for 
single nucleotide variant detection of 97.9% and 100%, respectively. The sensitivity for variant 
detection was notably better than the 88.3% achieved by whole exome sequencing (WES) using 
the same metrics, due to better coverage of targeted genes in the GEDi test compared to 
commercially available exome capture sets. Prospective testing of 192 patients with IRDs 
indicated that the clinical sensitivity of the GEDi test is high, with a diagnostic rate of 51%.
Conclusion—The data suggest that based on quantified performance metrics, selective targeted 
enrichment is preferable to WES for genetic diagnostic testing.
Keywords
Genetic diagnostic testing; next-generation sequencing; sensitivity; specificity; reproducibility
INTRODUCTION
Next-generation sequencing (NGS) based testing methods are increasingly being used for 
genetic diagnostic testing. This is especially true for genetically heterogeneous disorders, 
such as inherited retinal degenerations (IRDs), hearing loss, cardiomyopathies, 
mitochondrial disorders and cancer 1-4. There are multiple advantages to these approaches, 
including the ability to simultaneously sequence many genes and to quantify allele 
frequency 1,3,5,6. The Next-generation Sequencing: Standardization of Clinical Testing 
(Nex-StoCT) workgroup of the CDC and the American College of Medical Genetics and 
Genomics (ACMG) have issued guidelines for clinical laboratory standards for NGS-based 
testing methods, which include determination of test accuracy, analytical sensitivity and 
specificity, reproducibility and repeatability 7,8. Defining these test characteristics is 
important, and despite the increased use of NGS-based tests in Clinical Laboratory 
Improvement Amendments (CLIA) and/or College of American Pathologists (CAP) 
certified laboratories 3,6,9, the sensitivity, specificity and reproducibility of these techniques 
have been defined for only a small subset of tests 1,5,10.
Inherited eye disorders are important causes of vision loss. IRDs are among the most 
common causes of blindness in working age people 11, and glaucoma is a leading cause of 
irreversible blindness worldwide 12,13. Genetic diagnostic testing for these disorders is 
challenging due to their genetic heterogeneity. For example, mutations in over 200 genes 
can cause IRDs, and multiple genes are known to underlie inherited forms of glaucoma and 
optic atrophy (complete gene list available at: https://sph.uth.edu/retnet/) 14-16. It is 
increasingly desirable to obtain genetic diagnoses for patients with these disorders, as this 
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information can influence patient care by both informing genetic risk assessment and 
identifying patients who would benefit from novel gene-based therapies 17-21.
Recently, several groups have reported the use of NGS techniques for genetic diagnostic 
testing of patients with IRDs 22-26. These reports demonstrate that NGS combined with 
targeted enrichment approaches is a superior method for genetic diagnostic testing for 
patients with IRDs that improved diagnostic rates and reduced cost compared to traditional 
sequencing methods. In the reports published to date, however, the accuracy, sensitivity and 
specificity, reproducibility and repeatability of the NGS approaches used have not been 
completely defined.
We developed a targeted enrichment and NGS approach for genetic diagnostic testing of 
patients with inherited eye disorders, including IRDs, optic atrophy and glaucoma. In 
preparation for providing this Genetic Eye Disease (GEDi) test on a CLIA-certified basis, 
we sought to determine the accuracy, sensitivity and specificity, reproducibility and 
repeatability and clinical sensitivity of this testing approach compared with whole exome 
sequencing (WES).
MATERIALS and METHODS
Patient Samples
The clinical study was approved by the institutional review boards of the University of 
Pennsylvania and the Massachusetts Eye and Ear Infirmary, and conformed to the tenets of 
the Declaration of Helsinki. Informed consent was obtained from all participants, who were 
recruited after having been identified to have a form of inherited retinal degeneration 
following clincial evaluation by EAP or ABF at Mass Eye and Ear or Children's Hospital 
Boston, respectively. Genomic DNA (gDNA) was extracted from patient blood using the 
PreAnalytiX (QIAGEN / BD Biosciences; Valencia, CA) PAXgene Blood DNA Kit 
(PAXgene Blood DNA Kit Handbook, 10/2009) or DNAzol (Life Technologies, Carlsbad, 
CA).
Targeted Enrichment
i. Targeted Enrichment Bait Library Design—The custom SureSelect targeted 
enrichment GEDi capture kit (Agilent Technologies, Inc., Santa Clara, CA) was designed to 
capture and enrich coding exons, 5'-/3'-UTRs, and select deep intronic regions known to 
harbor pathogenic mutations, associated with the 214 known IRD disease genes described in 
the Retinal Information Network database (RetNet; https://sph.uth.edu/Retnet/) up to April 
2013, as well as 8 early-onset glaucoma and optic atrophy genes, using Agilent 
Technologies’ eArray web design tool (https://earray.chem.agilent.com/earray/). The GEDi 
capture kit also includes 24 candidate IRD disease genes, 9 age-related macular 
degeneration risk factor genes, and 1 non-syndromic hearing loss gene. Additional 
information regarding the parameters used for GEDi capture kit design is available in 
Supplemental Materials. The custom mitochondrial genome targeted enrichment baits we 
designed previously were also included as part of the GEDi capture kit 27. Complete lists of 
the GEDi targeted genes and intronic regions are shown in Tables S1a and S1b, respectively.
Consugar et al. Page 3
Genet Med. Author manuscript; available in PMC 2016 April 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
ii. Capture Library Sample Preparation—Illumina-compatible paired-end/
multiplexable GEDi targeted enrichment capture libraries were generated as described, using 
the following parameters: a) no less than 1.5 mcg of sheared gDNA was used for pre-capture 
library generation; b) 5-cycles of pre-capture PCR were used for all samples; c) no less than 
400 ng of pre-capture library was used during bait hybridizations; d) 14-cycles of post-
capture PCR were used to generate all capture libraries; e) all samples were post-capture 
indexed; and f) sample multiplex ratios were determined based on post-capture indexed 
sample concentrations (Agilent methods, part no.:G7530-90000; Protocol v2.1, May 2011).
NGS Analysis
GEDi targeted enrichment sample sequencing was performed on an Illumina MiSeq NGS 
platform (Illumina, Inc., San Diego, CA). A 12X patient sample multiplex was clustered to 
an average cluster density of between 750 - 900 K clusters per mm2 and 121 × 6 × 121 bp 
indexed/paired-end analyzed using Illumina's 300 cycle MiSeq Reagent Kit V2.
Whole Exome Sequencing
Whole exome capture and sequencing were performed as described in Supplementary 
Methods.
Informatics Analyses
Analysis of the sequence data obtained was performed using a combination of publically 
available and custom software tools, as described 28. Briefly, BWA (version 0.6.2-r126) was 
used to align the sequence reads to the human reference genome used by the 1000 Genomes 
Project . SAMtools (version 0.1.18 or r982:295) was used to remove potential duplicates, 
and make initial SNP and indel calls, which were refined using a custom program 28. A 
coverage depth cutoff of 10X was applied. Resulting variant calls were annotated using our 
custom human bp codon resource 28. Custom scripts were also developed and used to 
identify candidate variants that fit different filtering criteria, such as genetic models. 
Variants that fit the appropriate inheritance patterns, and were rare based on data from the 
1000 Genomes Project, the NHLBI Exome Sequencing Project Exome Variant Server, and 
our own internal controls were considered to be potentially pathogenic. See the 
Supplementary Methods section for addititional information.
RESULTS
GEDi Test Design
Probes were designed for 257 genes targeted by the GEDi selective capture system as well 
as the mitochondrial genome, since retinal degeneration and optic atrophy can accompany 
mitochondrial disease 27. Probes for previously identified deep intronic mutations in 
CEP290, OFD1, and USH2A have also been included in the GEDi probe set 29-31. The 
targeted regions constitute 1,210,190 bp in total (703,980 bp coding sequence), and are 
listed in Table S1.
Probes for some of the targeted regions could not be designed due to the presence of 
repetitive or non-unique sequence elements. In total, there were 688 such design gaps 
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ranging from 1-2,031 bp in length with an average length of 112 bp, accounting for a total of 
76,980 bp (9,220 bp coding sequence). Analysis of empiric GEDi data shows that design 
gaps ≤ 75 bp (67% of gaps) were relatively well covered by “near-target” capture (Figure 
1A).
NGS Metrics
Figure 1B shows a representative Depth-of-Coverage (DoC) plot for a 12x-multiplexed 
sample captured using the GEDi targeted enrichment kit and sequenced using an Illumina 
MiSeq. The data shows relatively uniform coverage of the target regions. The average 
percentages of the target regions covered at 1X (99.8%), 10X (98.6%) and 20X (96.4%) 
DoC were also relatively constant for all of the sequencing analyses. The 1.4% of target 
regions which were not covered with ≥ 10X read depth included part or all of 14 exons, The 
overall average DoC for all samples analyzed was 98.8X ± 14.5X.
Test Performance Metrics
The Nex-StoCT and ACMG recommend that validation of an NGS-based diagnostic test 
include performance test characteristics for assay accuracy, analytical sensitivity and 
specificity, reproducibility and repeatability 7,8. To measure these parameters for the GEDi 
capture and sequencing test, 4 samples (three randomly selected patient samples and the 
NA12878 HapMap sample) were prepared and sequenced in triplicate on each of three 
separate days. We also performed WES and SNP array genotyping analyses of these 4 
samples using Agilent V4+UTR whole exome enrichment kit and Illumina Omni 2.5 SNP 
arrays, respectively (see Supplemental Methods). The HapMap sample was included as an 
internal control for establishing QC metrics, and is included in all diagnostic runs to evaluate 
each diagnostic capture and sequencing run.
Sensitivity and Specificity
To assess the sensitivity and specificity of the GEDi test, we used the 2,443 SNPs located in 
GEDi genes that are represented on Omni 2.5 SNP array, using the Omni 2.5 data as the 
“gold standard.” For these analyses, sensitivity was calculated as the ability of the GEDi test 
to correctly identify a SNP when it was identified in the Omni 2.5 data. Similarly, the 
specificity was calculated as the ability of the GEDi test to correctly identify the lack of a 
variant at a given position when reference was detected by the Omni 2.5 array 5 (Table 1). 
For example, 495 ± 1 SNPs identified in the 9 GEDi replicates for the OGI-132-357 sample 
(range 492-497) were also identified in the Omni 2.5 data, and these were scored as true 
positives (Table 1). The GEDi test did not identify variants at 10 ± 1.4 positions where 
variants were identified in the Omni 2.5 data for OGI-132-357, and these were scored as 
false negatives, giving a sensitivity of 0.98 for variant detection. The GEDi test did not 
identify variants at any of the 1,919 SNPs with reference genotypes in the Omni 2.5 data, for 
a specificity of 1 (Table 1). The average sensitivity of the GEDi test, including data from the 
9 replicates of all 4 samples, was 0.979 ± 0.007, and the specificity was 1 ± 0.
We investigated the false negative base calls in the GEDi data further and found that there 
were 7-11 discrepancies per sample identified between the GEDi and Omni 2.5 data (Table 
2). In total, there were discrepancies detected at 23 positions that were predominantly related 
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to the heterozygous vs. homozygous state of the same identified base, with a different base 
identified at only 1 position, chr15:78397352. The NGS data showed that at chr15:78397352 
the Omni data were incorrect due to a single base deletion adjacent to the interrogated base, 
which shifted the base analyzed by the single-base extension method used in the Omni 
arrays (Figure 2A). Indels were associated with 4 additional GEDi vs. Omni discrepancies, 
and all but one of the remaining differences were due to low SNP quality scores in the 
SAMtools variant identification software (Table 2). At one position (chr4:6304087), the 
Omni data was incorrect (confirmed by Sanger sequencing), without any evident 
explanation. A small number (7-10) of bases were not called in the GEDi data across all 
replicates (No Call, Figure 2C), and Omni 2.5 SNP calls were not obtained for 11-19 
positions (Omni No Value, Figure 2C). Bases were scored as “No Call/Match” if 1 or more 
replicates for each DNA sample had no call at that position, but all other replicates matched. 
There were 25-45 of these bases, with many of these (55/87 total = 63%) being due to no 
call in a single replicate (Table S2).
The accuracy of the GEDi test was also supported by comparison of the GEDi sequence data 
for the HapMap sample NA12878 with publically available Platinum 200X average depth 
WGS data for NA12878 from Illumina (http://www.illumina.com/platinumgenomes). 
Within the 1,197,667 bp in the GEDi capture regions, excluding the mitochondrial 
chromosome, there were 962 SNPs and 89 indels identified in the NA12878 WGS data by 
Illumina. The accuracy of the GEDi test to identify both the SNPs and indels was 99.9%. 
The sensitivity and specificity for SNP detection were 96.4% and 99.9%, and for indel 
detection were 91.6% and 99.9%, respectively. It is likely that the sensitivity of the GEDi 
test for SNP detection is even higher, as we identified 47 SNPs called in the Illumina 
Platinum data that are located in a highly repetitive 11 kb chr17 region 
(chr17:21311917-21323163) in the gene KCNJ12 that are likely to be incorrect due to poor 
read alignment (Figure S1).
GEDi vs. WES
The GEDi test performance was compared to WES by analyzing the WES data of the same 
4 validation samples for the 2,443 Omni 2.5 SNPs in the GEDi gene set. The average depth 
of coverage achieved by WES in these experiments was 100X, with 98% of the targeted 
regions covered at 10X sequence depth. Using the Omni 2.5 data as the “gold standard,” the 
sensitivity of WES was 0.883 ± 0.004, and the specificity of WES was 0.9998 ± 0.0003. 
While both GEDi and WES have excellent specificity, this comparison shows that WES is 
approximately 10% less sensitive than the GEDi test. Analysis shows that this is due to lack 
of sequence coverage in the WES data, with approximately 10% of the 2,443 positions 
interrogated in these analyses having insufficient coverage (≥10X) to make an accurate base 
call (Table S3). The majority of these positions (76%) were common in all 4 samples, 
suggesting that these positions were covered less efficiently in the WES capture design. 
Comparison of the WES and GEDi capture baits at these positions confirmed this 
hypothesis, and showed that 88% of the positions without coverage in the WES data had no 
baits in the V4+UTR capture set, whereas the GEDi capture set had at least 1 bait at these 
positions (Table S3). An example of one of these regions in shown in Figure 3. Further, 
there are 947 mutations in IRD disease genes reported in HGMD, ClinVar and Ensemble 
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that would be detected by GEDi sequencing which fall in regions that are not covered in the 
Agilent V4+UTR WES capture set (Table S4). Conversely, WES did detect bases at an 
average of 5.5 positions out of 2,443 (0.22%) for which GEDi sequencing provided no call.
Reproducibility and Repeatability
The reproducibility of variant detection by GEDi was assessed by comparing the detection 
rates for the 2,443 common SNPs in all 9 GEDi datasets from each of the 4 samples. Bases 
that were discrepant in 1 or more of the 9 datasets for each sample in this “GEDi vs. GEDi” 
comparison were identified. GEDi capture followed by Illumina sequencing is highly 
reproducible, with only 4-6 discrepancies detected between the replicates for each DNA 
sample. In each case, the discrepancies related to the heterozygous vs. homozygous state of 
the same identified base. In the majority of cases, one out of the 9 sequence runs performed 
for each DNA sample contained the discrepancy (Table S5). Further analysis of the data for 
each of the 17 total discrepancies showed that they were due to low SNP quality score in the 
SAMtools variant identification software. Sixteen of these are the same as those detected in 
the GEDi vs. Omni 2.5 comparisons described above (Table S5).
The repeatability and reproducibility of the GEDi test was also evaluated using the kappa 
statistic, or kappa coefficient of agreement 32. For GEDi replicates performed on the same 
day the kappa statistic was 0.83088, indicating almost perfect agreement between the data 
obtained in the three replicates for each DNA sample analyzed 32. For GEDi tests performed 
for the 4 individual samples on each of the three separate days the kappa statistic was 
0.76366, indicating excellent reproducibility 32.
Mutation Detection
The GEDi test correctly identified mutations in 17/18 patient samples with known IRDs, 
glaucoma and optic atrophy variants, including 10 indels (Table S6). GEDi testing did not 
correctly identify the pathogenic FOXC1 indel mutation in a patient with glaucoma; 
however, analysis showed a design gap in FOXC1 where this pathogenic mutation is 
located.
Clinical Sensitivity
GEDi clinical sensitivity was analyzed using samples from 192 probands with diagnoses of 
isolated or syndromic IRD, albinism or microphthalmos (Table S7). Analyses of the 
sequence data identified genetic diagnoses for 98 of the probands, representing a clinical 
sensitivity of 51%, consistent with findings from other studies (Table S7) 22-26. The majority 
of these diagnoses were consistent with the subject's clinical presentation and family history. 
Two subjects without a family history of disease were found to have mutations in the known 
dominant IRD disease genes PRPH2 and IMPDH1, consistent with identification of de novo 
mutations in the affected individuals; segregation analyses confirmed de novo mutations in 
these two subjects (OGI-301-703 and OGI-274-582, Table S7). While de novo mutations 
have been reported as the cause of dominant RP, de novo mutations in the PRPH2 and 
IMPDH1 genes have not been previously reported. The majority of subjects that were not 
diagnosed genetically by GEDi testing had non-syndromic RP (52/89 = 58%; Table S8).
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Mutation Validation
In total, we identified 147 likely pathogenic mutations by GEDi capture and NGS 
sequencing, and all but four of these were validated by PCR and Sanger sequencing 
(Supplemental methods and Table S9). Review of the NGS data for the 4 putative mutations 
that were not validated by Sanger sequencing showed that 3 of the 4 mutations, 
corresponding to 2 probands (OGI-040-100 and OGI-271-579) were detected by less than 10 
reads (Table S9). The 4th putative mutation not detected by Sanger sequencing, had 
excellent DoC (Table S9); however, the heterozygous G base call was due to mis-alignment 
of some of the NGS sequence reads, resulting in a false positive variant call (Figure 2B).
Missed Diagnoses
GEDi capture and sequencing did not initially identify a genetic cause of disease in 5 
patients for whom genetic diagnoses were ultimately obtained (Table S10). These cases are 
instructive, and information from them has been used to iteratively improve the GEDi test. 
For example, in two cases, OGI-147-394 and OGI-387-839, GEDi sequencing identified a 
single potentially pathogenic variant in ABCA4 and USH2A, respectively, but the second 
mutant allele was not initially detected (Table S10). The second alleles were subsequently 
identified by Sanger sequencing, both being deep intronic mutations known to alter 
splicing 31,33. Probes for the relevant intronic region for USH2A have been added to 
subsequent versions of the GEDi capture set (Table S1b), and those corresponding to deep 
intronic ABCA4 mutations will be added to the next version of GEDi 33. Information 
regarding the remaining 3 cases listed in Table S10 is included in Supplementary 
Information.
Improved Diagnoses
Of note, seven of the subjects studied were found to have mutations in genes that are not 
primarily associated with their phenotypes (denoted with * in Table S7). Specific examples 
include cone dystrophy due to mutations in the ORF15 region of RPGR, NRL mutations in 
Chorio-retinal atrophy, and TMEM67 mutations in Senior-Loken syndrome (additional 
details in Supplemental Information).
DISCUSSION
Our results suggest that selective targeted enrichment and NGS is the preferred method for 
diagnostic testing, especially for genetically heterogeneous disorders such as IRDs. The 
GEDi test has improved sensitivity when compared to WES while maintaining nearly 
perfect specificity. Our results show that the higher sensitivity of the GEDi test is due to 
improved probe design compared to commercially available exome capture sets where 
probes were missing for approximately 10% of the regions targeted by the GEDi test. While 
the concept that targeted sequencing can out-perform standard exome sequencing based on 
better coverage has been discussed in reviews and commentaries regarding genetic 
diagnostic testing, only limited empiric comparisons of these two approaches to genetic 
diagnostic testing have been reported previously 3,10,34. Thus, while WES is now available 
as a clinical diagnostic test at some centers, and reports of using WES for diagnostic testing 
have been published, quantitation of the performance characteristics of the GEDi test makes 
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it possible to identify and quantify the advantages of selective targeted enrichment over 
WES 6,35,36.
There are additional advantages of selective enrichment or panel tests over WES for 
diagnostic testing. The turn-around-time for the GEDi “panel” test run on a MiSeq NGS 
platform is approximately 1 day, which is considerably less than WES samples run on a 
HiSeq 2000 instrument (~12 days). The current costs of selective exon capture tests are also 
lower than WES, although it is likely that this difference will continue to diminish over time. 
At present (8/2014), the cost of the materials needed for GEDi testing per patient is 
approximately $430, compared to $1,325 per patient for WES using the sequence depth 
described. In addition, panel testing has a higher pre-test probability of finding a meaningful 
result, and reduces the potential for making incidental sequence findings, which can be 
challenging for both health care providers and patients 37,38.
While multiple characteristics make selective targeted enrichment a preferable method for 
genetic diagnostic testing, there are some drawbacks to this approach. First, hybridization-
based capture approaches are limited by “design gaps”, regions where it is not possible to 
design targeted enrichment probes. Specifically, genome regions with high GC content 
and/or repetitive elements can be resistant to accurate capture probe design 3. Fortunately, 
based on the data obtained for the GEDi test, near-target sequence coverage limits this 
problem to gaps larger than 75 bp, which reduces, although does not, eliminate this problem. 
It is also possible to use alternative approaches to capture regions in hybridization design 
gaps, including amplification-based strategies such as Agilent Technologies’ HaloPlex 
technique 39.
Sufficient sequence depth is also needed to make accurate base calls from the NGS data. For 
GEDi we showed that a minimum depth of coverage of 10X gave a specificity of 100%. 
Even with sufficient depth of coverage, mis-alignment of short NGS reads can lead to 
incorrect base identification, especially for repetitive regions or genes with paralogous 
copies elsewhere in the genome, which we observed in both the GEDi and WES data. Until 
longer sequencing reads become routinely available, this is likely to remain a problem; 
however, familial segregation studies and Sanger validation of pathogenic alleles can be 
useful to resolve these discrepancies.
We carefully evaluated the overall performance characteristics of the GEDi test and showed 
that the test is both sensitive and specific and is highly reproducible and accurate. Thorough 
analyses of these test characteristics have been reported for one other NGS-based diagnostic 
test, a targeted enrichment and NGS-based test for 25 genes associated with cancer called 
the WUCaMP assay 5. The sensitivity and specificity of the WUCaMP assay were 
determined by comparing test data with WGS data from Complete Genomics for HapMap 
sample NA19240. For these studies, the test samples were sequenced to a high depth of 
coverage, with 96.9% of the targeted regions covered at ≥ 50X depth. The reported 
sensitivity and specificity for detecting SNVs were 98.3% and 100%, respectively 5. The 
sensitivity and specificity of the GEDi test for SNV detection are comparable, at 96.4% to 
97.9% and 99.9% to 100%, respectively, with an overall accuracy for both the SNPs and 
indels of 99.9%. We also showed that the GEDi test is highly repeatable and reproducible, 
Consugar et al. Page 9
Genet Med. Author manuscript; available in PMC 2016 April 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
with kappa statistics of 0.83088 and 0.76366, respectively, indicating excellent agreement 
between the data obtained in the replicate testing of the 4 individual DNA samples 32.
The clinical sensitivity of the GEDi test was 51% in patients with IRDs, a rate that is 
consistent with prior reports 22-26. It is hypothesized that subjects without mutations in 
GEDi target genes must have mutations in novel disease genes, or in non-coding portions of 
the currently identified IRD disease genes. Exome and genome sequencing will be required 
for identifications of these mutations. It is also possible that some subjects have mutations 
that cannot be readily detected by sequencing-based approaches, such as CNVs 25,40.
Comprehensive genetic diagnostic testing for genetically and phenotypically heterogeneous 
disorders such as IRDs can also lead to diagnoses outside of the reported genotype-
phenotype relationships. Seven of the patients with genetic diagnoses had atypical 
phenotypic features confirming that it can be difficult to predict the genetic cause of disease 
based on clinical findings alone 26.
In summary, the GEDi test offers a number of advantages as a clinical diagnostic test for 
patients with inherited eye disorders. Given the potential for gene-based therapies for 
inherited disorders in general, and inherited eye disorders specifically, genetic diagnostic 
testing will increasingly be necessary for optimal care of patients with genetic diseases. 
Further, the GEDi test statistics make a strong case for the use of targeted tests in the clinical 
setting, as they are highly accurate, reproducible and have better overall performance than 
more general tests such as conventional WES analyses.
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Figure 1. 
(A) Analysis of empiric GEDi data shows that design gaps ≤ 75 bp were relatively well 
covered by “near-target” capture. (B) Representative Depth-of-Coverage (DoC) plot for a 
12x-multiplexed capture sample using the GEDi targeted enrichment kit and 2 × 121 bp 
paired-end sequenced using an Illumina MiSeq.
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Figure 2. 
(A) Integrative Genomics Viewer (IGV) screenshot of representative GEDi NGS validation 
data at chr15:78397352. The Omni 2.5 SNP data were determined to be incorrect in all 
samples due to a single base deletion adjacent to the interrogated base that shifted the 
analyzed base. (B) IGV screenshot of the putative c.1028T>G mutation of FSCN2 in 
OGI-267-573, clarifying the false positive variant call was due to mis-alignment of some 
NGS sequencing reads. (C) GEDi vs. Omni 2.5 concordance histogram plot corresponding 
to the 2,443 shared SNPs between the GEDi design and Omni 2.5 SNP for all 36 replicates 
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of the 4 validation samples used in this study. KEY: MATCH – All GEDi NGS replicates 
matched Omni 2.5 SNP data; NO CALL – no NGS result; NO MATCH – ≥ 1 NGS replicate 
did not match Omni 2.5 SNP data; OMNI NO VALUE – no Omni 2.5 SNP result; NO 
CALL/MATCH – ≥ 1 NGS replicate had no result; all other NGS replicates matched Omni 
2.5 SNP data.
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Figure 3. 
Comparison of V4+UTR WES and GEDi capture baits at the 5′-end of ABCC6. The ABCC6 
reference used is a “collapsed” reference that accounts for all known gene isoforms.
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Table 1
Sensitivity and specificity calculations for GEDi vs. Omni 2.5 SNP data.
2 × 2 Contingency Table
Omni + (SNP) Omni - (REF)
GEDi + (SNP) True Positive False Positive
GEDi - (REF) False Negative True Negative
Sensitivity = True Pos/(True Pos + False Neg) Specificity = True Neg/(True Neg + False Pos)
NA12878
Omni + (SNP) Omni - (REF)
GEDi + (SNP) 508 (503-510 SD:2) 0 (0-0 SD:0)
GEDi - (REF) 12 (8-20 SD:4) 1933 (1919-1944 SD:13)
Sensitivity: 0.977 (0.967-0.981 SD:0.004) Specificity: 1 (1-1 SD:0)
OGI-281-608
Omni + (SNP) Omni - (REF)
GEDi + (SNP) 469 (462-472 SD:3) 0 (0-0 SD:0)
GEDi - (REF) 13 (10-20 SD:3) 1944 (1944-1944 SD:0)
Sensitivity: 0.973 (0.959-0.979 SD:0.007) Specificity: 1 (1-1 SD:0)
OGI-132-357
Omni + (SNP) Omni - (REF)
GEDi + (SNP) 495 (492-497 SD:1) 0 (0-0 SD:0)
GEDi - (REF) 10 (8-13 SD:1.4) 1919 (1919-1919 SD:0)
Sensitivity: 0.981 (0.974-0.984 SD:0.003) Specificity: 1 (1-1 SD:0)
OGI-307-717
Omni + (SNP) Omni - (REF)
GEDi + (SNP) 508 (506-511 SD:1.716) 0 (0-0 SD:0)
GEDi - (REF) 7 (4-9 SD:2) 1917 (1917-1917 SD:0)
Sensitivity: 0.986 (0.983-0.992 SD:0.003) Specificity: 1 (1-1 SD:0)
For each DNA sample, the number of positions at which variants (SNP) or reference (REF) were detected by the Omni 2.5 SNP arrays and GEDi 
test are indicated. For the GEDi data, the ranges derived from the 9 replicates for each sample tested are shown. The average sensitivity and 
specificity for each DNA sample are shown, with the ranges and standard deviation (SD) included in parentheses. The overall sensitivity and 
specificity reported in the text are the averages of these data for all 4 samples. A standard 2×2 contingency table with definitions of sensitivity and 
specificity is shown for reference.
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Table 2
GEDi vs. Omni 2.5 Discrepancies Detected.
NA12878 OGI-132-357 OGI-281-608 OGI-307-717 DISCREPANCY
chr1:156146218 1/9 HOM/HET 1
chr1:213071341 1/9 HOM/HET 1
chr2:62052380 1/9 HOM/HET 1
chr2:166770120 3/8 HOM/HET 1
chr3:150645351 2/9 HOM/HET 1
chr3:193413502 1/5 HOM/HET 1
chr4:15982166 2/7 HOM/HET 1
chr5:178405941 2/9 HOM/HET 1/9 HOM/HET 1
chr6:42932200 1/7 HOM/HET 1/3 HOM/HET 1/7 HOM/HET 1
chr6:42932202 1/8 HOM/HET 1/7 HOM/HET 1
chr9:102861613 1/9 HOM/HET 1
chr9:139327064 9/9 HOM/HET 9/9 HOM/HET 9/9 HOM/HET 1
chr10:73461805 1/9 HOM/HET 1
chr10:85976966 9/9 HOM/HET 9/9 HOM/HET 1
chr16:1265600 1/7 HOM/HET 1
chr16:1574863 1/9 HOM/HET 1
chr16:57937788 1/9 HOM/HET 1
chr17:11835331 1/9 HOM/HET 1
chr3:63986047 9/9 HOM/HET 9/9 HOM/HET 2
chr4:6304087 9/9 HOM/HET 5
chr4:15981874 9/9 HOM/HET 4
chr4:15982166 9/9 HOM/HET 9/9 HOM/HET 4
chr11:76895772 9/9 HOM/HET 9/9 HOM/HET 2
chr15:78397352 9/9 DISCREP 9/9 DISCREP 9/9 DISCREP 9/9 DISCREP 3
Base positions of discrepancies detected in at least 1 GEDi sequence replicate and the Omni 2.5 SNP data for each sample analyzed are shown. The 
number of replicates with alternate results are indicated. Fewer than 9 replicates are indicated for some positions at which base calls were not made 
in some replicates. Discrepancies located in the top portion of the table were due to low SNP quality scores in SAMtools; the bottom portion of the 
table contains discrepancies specific to the GEDi vs. Omni data comparisons. The reasons identified for the discrepancies are indicated in the right 
column: 1 = low SNP quality score; 2 = heterozygous deletion of target base; 3 = homozygous deletion adjacent to target base; 4 = heterozygous 
insertion adjacent to target base; 5 = Omni incorrect, reason uncertain. Note that position chr4:15982166 is included in both halves of the table.
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